Synthego, a Redwood City, Calif.-based genome engineering company, raised $100m in Series D financing.
The round was led by new investor Wellington Management, co-led by RA Capital Management and 8VC. Additional investors included Founders Fund, Menlo Ventures, and Intel Capital. This new round brings Synthego’s total private funding to more than $250m. The company, which also recently appointed biopharma and technology industry veterans Robert (Bob) Deans, Ph.D., as Chief Scientific Officer, and John Tan, M.B.A., as Chief Operating Officer, will use the proceeds from the financing to expand the capabilities of its proprietary platforms.
Led by Paul Dabrowski, CEO and Co-Founder, Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation and gene editing to build platforms for science at scale. has developed platforms designed to produce standardized CRISPR reagents and engineered cells to enable more rapid and precise discovery, validation and genetic pathway analysis that scientists use to conduct basic research, target identification and clinical trials.
Robert Deans, Ph.D., brings more than 25 years of experience developing stem cell and gene therapies, as well as translational science and global regulatory expertise to Synthego, where he will serve as Chief Scientific Officer. With previous executive roles at BlueRock Therapeutics and Rubius Therapeutics, Deans’ experience includes the creation of next-generation therapies by harnessing pluripotent stem cell biology and gene editing tools. Deans has been influential in standardizing stem and progenitor cell practices during his participation in several stem cell and therapeutic societies, including serving on multiple committees at the Alliance for Regenerative Medicine (ARM), and the International Society for Stem Cell Research (ISSCR).
John Tan, M.B.A., joining Synthego as Chief Operating Officer, brings decades of global operations and automation expertise across technology and life sciences companies, including Amazon and Thermo Fisher Scientific. During his tenure at Amazon, Tan was responsible for engineering design and capital procurement at a multi-billion-dollar group for Amazon’s worldwide fulfillment centers, transportation logistics and automation and robotics capabilities. Before Amazon, Tan led global operations at Thermo Fisher where he managed global planning, quality, regulatory, procurement, supply chain and continuous improvement functions across more than 20 sites located in the U.S., Europe and Asia.